Switch theme
Sign up to access all valuation multiples
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
1992
5
LTM Revenue $4.6M
LTM EBITDA -$12.6M
-$1.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Marker Therapeutics has a last 12-month revenue (LTM) of $4.6M and a last 12-month EBITDA of -$12.6M.
In the most recent fiscal year, Marker Therapeutics achieved revenue of $6.6M and an EBITDA of -$4.5M.
Marker Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Marker Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.6M | XXX | $6.6M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$12.6M | XXX | -$4.5M | XXX | XXX | XXX |
| EBITDA Margin | -272% | XXX | -69% | XXX | XXX | XXX |
| EBIT | -$18.3M | XXX | -$4.5M | XXX | XXX | XXX |
| EBIT Margin | -394% | XXX | -69% | XXX | XXX | XXX |
| Net Profit | -$18.1M | XXX | -$10.7M | XXX | XXX | XXX |
| Net Margin | -390% | XXX | -163% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Marker Therapeutics's stock price is $2.
Marker Therapeutics has current market cap of $17.1M, and EV of -$1.0M.
See Marker Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$1.0M | $17.1M | XXX | XXX | XXX | XXX | $-1.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Marker Therapeutics has market cap of $17.1M and EV of -$1.0M.
Marker Therapeutics's trades at -0.2x EV/Revenue multiple, and 0.2x EV/EBITDA.
Equity research analysts estimate Marker Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Marker Therapeutics has a P/E ratio of -0.9x.
See valuation multiples for Marker Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17.1M | XXX | $17.1M | XXX | XXX | XXX |
| EV (current) | -$1.0M | XXX | -$1.0M | XXX | XXX | XXX |
| EV/Revenue | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.9x | XXX | -1.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMarker Therapeutics's last 12 month revenue growth is -40%
Marker Therapeutics's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $2.2M for the same period.
Marker Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Marker Therapeutics's rule of X is -372% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Marker Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -40% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -272% | XXX | -69% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | -2% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -108% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -372% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 204% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 169% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Marker Therapeutics acquired XXX companies to date.
Last acquisition by Marker Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Marker Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Marker Therapeutics founded? | Marker Therapeutics was founded in 1992. |
| Where is Marker Therapeutics headquartered? | Marker Therapeutics is headquartered in United States of America. |
| How many employees does Marker Therapeutics have? | As of today, Marker Therapeutics has 5 employees. |
| Who is the CEO of Marker Therapeutics? | Marker Therapeutics's CEO is Dr. Juan Vera, M.D.. |
| Is Marker Therapeutics publicy listed? | Yes, Marker Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Marker Therapeutics? | Marker Therapeutics trades under MRKR ticker. |
| When did Marker Therapeutics go public? | Marker Therapeutics went public in 1998. |
| Who are competitors of Marker Therapeutics? | Similar companies to Marker Therapeutics include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Marker Therapeutics? | Marker Therapeutics's current market cap is $17.1M |
| What is the current revenue of Marker Therapeutics? | Marker Therapeutics's last 12 months revenue is $4.6M. |
| What is the current revenue growth of Marker Therapeutics? | Marker Therapeutics revenue growth (NTM/LTM) is -40%. |
| What is the current EV/Revenue multiple of Marker Therapeutics? | Current revenue multiple of Marker Therapeutics is -0.2x. |
| Is Marker Therapeutics profitable? | Yes, Marker Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Marker Therapeutics? | Marker Therapeutics's last 12 months EBITDA is -$12.6M. |
| What is Marker Therapeutics's EBITDA margin? | Marker Therapeutics's last 12 months EBITDA margin is -272%. |
| What is the current EV/EBITDA multiple of Marker Therapeutics? | Current EBITDA multiple of Marker Therapeutics is 0.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
